Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 4/20 | 0.76 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.56 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.56 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.56 |
| ▸ | TYMS | P04818 | 5/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Deoxyuridine Monophosphate SCHEMBL8200 | 0.92 | DUT (0.77) | DUTTYMS | |
| Deoxyuridine Monophosphate SCHEMBL21941035 | 0.92 | DUT (0.77) | DUTTYMS | |
| Deoxyuridine Monophosphate SCHEMBL25024676 | 0.92 | DUT (0.77) | DUTTYMS | |
| Deoxyuridine Monophosphate SCHEMBL888328 | 0.92 | DUT (0.77) | DUTTYMS | |
| SCHEMBL4263613 | 0.89 | DUT (0.73) | DUTP2RY2P2RY4P2RY6TYMS | |
| SCHEMBL5565558 | 0.89 | DUT (0.73) | DUTP2RY2P2RY4P2RY6TYMS | |
| SCHEMBL21626116 | 0.88 | DUT (0.78) | DUTP2RY2P2RY4P2RY6 | |
| SCHEMBL21067966 | 0.88 | DUT (0.78) | DUTP2RY2P2RY4P2RY6 | |
| SCHEMBL22198883 | 0.88 | DUT (0.75) | DUTP2RY2P2RY4P2RY6 | |
| SCHEMBL156694 | 0.88 | DUT (0.78) | DUTP2RY2P2RY4P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040102409-A1 | Medicament for locally treating or preventing a chemotherapy-induced mucositis and other side effects resulting from chemotherapy | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2004-05-27 | — | — | US | claimed |
| EP-1414482-A2 | MEDICAMENT FOR LOCALLY TREATING OR PREVENTING A CHEMOTHERAPY-INDUCED MUCOSITIS AND OTHER SIDE EFFECTS RESULTING FROM CHEMOTHERAPY | Geurtsen, Werner (DE) | 2004-05-06 | — | — | EP | claimed |
| WO-2002047709-A2 | RESISTANT THYMIDYLATE SYNTHASE MUTANTS FOR LOCALLY TREATING A CHEMOTHERAPY-INDUCED MUCOSITIS AND OTHER SIDE EFFECTS ASSOCIATED WITH CHEMOTHERAPY | GEURTSEN WERNER (DE) | 2002-06-20 | — | — | WO | claimed |
| US-5534519-A | 5,10,-methylene-tetrahydrofolate as a modulator of a chemotherapeutic agent | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1996-07-09 | — | — | US | claimed |
| WO-1991017660-A1 | 5,10-METHYLENE-TETRAHYDROFOLATE AS A MODULATOR OF A CHEMOTHERAPEUTIC AGENT | SPEARS COLIN P (US) | 1991-11-28 | — | — | WO | claimed |
| EP-4735116-A2 | ANTI-TRAILR2 ANTIGEN-BINDING PROTEINS AND USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4648792-A2 | ANTI-TNFR2 ANTIGEN-BINDING PROTEINS AND USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2025-11-19 | — | — | EP | disclosed |
| WO-2025217240-A1 | ANTI-TNFR2 ANTIGEN-BINDING PROTEINS AND USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| CN-120129702-A | RNA compositions targeting claudin-18.2 | 生物技术公司 | 2025-06-10 | — | — | CN | disclosed |
| US-12325859-B2 | Microbial approach for the production of long chain compounds | UT-BATTELLE, LLC (US) | 2025-06-10 | — | — | US | disclosed |
| WO-2025080751-A2 | ANTI-CDH17 ANTIGEN-BINDING PROTEINS AND USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| WO-2025006846-A2 | ANTI-TRAILR2 ANTIGEN-BINDING PROTEINS AND USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2025-01-02 | — | — | WO | disclosed |
| US-6258360-B1 | BENZOATE CONJUGATES; ANTITUMOR AGENTS | IGEN INTERNATIONAL, INC. | 2001-07-10 | — | — | US | disclosed |
| WO-2001019320-A2 | PHOSPHOLIPID PRODRUGS OF ANTI-PROLIFERATIVE DRUGS | D-PHARM LIMITED (IL) | 2001-03-22 | — | — | WO | disclosed |
| EP-0746336-A1 | PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS | IGEN, INC. (US) | 1996-12-11 | — | — | EP | disclosed |
| EP-0746336-A4 | PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS | IGEN INC (US) | 1996-07-26 | — | — | EP | disclosed |
| US-5534519-A | 5,10,-methylene-tetrahydrofolate as a modulator of a chemotherapeutic agent | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1996-07-09 | — | — | US | disclosed |
| US-5376658-A | 5,10-methylene-tetrahydrofolate as a modulator of a chemotherapeutic agent | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1994-12-27 | — | — | US | disclosed |
| WO-1993002703-A1 | PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS | IGEN, INC. (US) | 1993-02-18 | — | — | WO | disclosed |
| WO-1991017660-A1 | 5,10-METHYLENE-TETRAHYDROFOLATE AS A MODULATOR OF A CHEMOTHERAPEUTIC AGENT | SPEARS COLIN P (US) | 1991-11-28 | — | — | WO | disclosed |